» Articles » PMID: 20563709

PDK1: the Major Transducer of PI 3-kinase Actions

Overview
Date 2010 Jun 22
PMID 20563709
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Most of the cellular responses to phosphatidylinositol 3-kinase activation and phosphatidylinositol 3,4,5-trisphosphate production are mediated by the activation of a group of AGC kinases comprising PKB, S6K, RSK, SGK and PKC isoforms, which play essential roles in regulating physiological processes related to cell growth, proliferation, survival and metabolism. All these growth-factor-stimulated AGC kinases possess a common upstream activator, namely PDK1, a master kinase, which, being constitutively active, is still able to phosphorylate and activate its AGC substrates in response to rises in the levels of the PtdIns(3,4,5)P(3) second messenger. In this chapter, the biochemical, structural and genetic data on the mechanism of action and physiological roles of PDK1 are reviewed, and its potential as a pharmaceutical target for the design of drugs therapeutically beneficial to treat human disease such us diabetes and cancer is discussed.

Citing Articles

Development of Sheep Intestinal Organoids for Studying Deoxynivalenol-Induced Toxicity.

Wang H, He X, Zhang M, Fan N, Yang Z, Shen T Int J Mol Sci. 2025; 26(3).

PMID: 39940725 PMC: 11816529. DOI: 10.3390/ijms26030955.


The Importance of Phosphoinositide 3-Kinase in Neuroinflammation.

Wright B, King S, Suphioglu C Int J Mol Sci. 2024; 25(21).

PMID: 39519189 PMC: 11546674. DOI: 10.3390/ijms252111638.


Exploring temporal and sex-linked dysregulation in Alzheimer disease phosphoproteome.

Yilmaz S, Lopes F, Schlatzer D, Wang R, Qi X, Koyuturk M iScience. 2024; 27(10):110941.

PMID: 39391719 PMC: 11465087. DOI: 10.1016/j.isci.2024.110941.


3-Phosphoinositide-Dependent Kinase 1 as a Therapeutic Target for Treating Diabetes.

Xiang X, Shuya P, Jiamin Z, Zihan Z, Xumei Y, Jingjin L Curr Diabetes Rev. 2024; 21(4):47-56.

PMID: 38468518 DOI: 10.2174/0115733998278669240226061329.


A novel small molecule, CU05-1189, targeting the pleckstrin homology domain of PDK1 suppresses VEGF-mediated angiogenesis and tumor growth by blocking the Akt signaling pathway.

Park J, Zhang H, Kwak H, Gadhe C, Kim Y, Kim H Front Pharmacol. 2023; 14:1275749.

PMID: 38035024 PMC: 10687218. DOI: 10.3389/fphar.2023.1275749.